b>j)΄!Pԫ&;"kB޶}pSVT(wę!j x;-m@JnQ+պכ7MajfJͱ4jѲ撆RxZMz7vIW/dٞТזcZM~ji ߒsQzԠDW3Den"M+/B:-uIJ7j委9p='mANޭ=/B:-n&nUfqxZM~c Ϲ+,&ᾺܢF[(1*" ϒ"Jԧ<;b" "jܢF[x ,!q қ*]/؝27SMcs"ޭDQ/应ܢF_! :s" 7`F+SVTn"IJnQ/应B 4 wD"IJ׭-`S9DrjiEJ߅gJ应矁[xZM~n"IB؃!'Тѕ+(mIKʭ/|ϐܢF[xZMzG %嬩/c[[\n

Rymti is an etanercept biosimilar that belongs to the class of medications called biological response modifiers (“biologics”) or tumor necrosis factor inhibitors (TNF blockers). People with inflammatory conditions produce extra amounts of tumor necrosis factor (TNF), a protein that causes pain, inflammation, and tissue damage. Rymti binds to TNF and blocks its activity, helping reduce inflammation in the joints and on the skin.<\/p>\n

The medication offers several key benefits:<\/p>\n